The recent wave of layoffs and financial troubles at CRISPR-focused startups should not tarnish the promise of CRISPR.

A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.

However, sell-offs present great opportunities to buy stocks with significant upside potential. Further, CRISPR Therapeutics ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Gene editing and many other useful biotechnology tools came from studies of bacteria fighting off viral invaders. But ...

Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.

Eyeing a future of improved patient outcomes, the Medical College of Wisconsin is working to advance the prevention, ...

A research team has developed an advanced delivery system that transports gene-editing tools based on the CRISPR/Cas9 gene-editing system into living cells with significantly greater efficiency than ...

In a nutshell Cambridge researchers developed a new DNA classification system that reveals hidden patterns in cancer, ...

Genomics Market Liquid Biopsy Liquid biopsy is a non-invasive method for detecting cancer by analyzing blood samples for genetic mutations ...

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...